Your browser doesn't support javascript.
loading
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.
Tsao, Anne S; Lindwasser, O Wolf; Adjei, Alex A; Adusumilli, Prasad S; Beyers, Matthew L; Blumenthal, Gideon M; Bueno, Raphael; Burt, Bryan M; Carbone, Michele; Dahlberg, Suzanne E; de Perrot, Marc; Fennell, Dean A; Friedberg, Joseph; Gill, Ritu R; Gomez, Daniel R; Harpole, David H; Hassan, Raffit; Hesdorffer, Mary; Hirsch, Fred R; Hmeljak, Julija; Kindler, Hedy L; Korn, Edward L; Liu, Geoffrey; Mansfield, Aaron S; Nowak, Anna K; Pass, Harvey I; Peikert, Tobias; Rimner, Andreas; Robinson, Bruce W S; Rosenzweig, Kenneth E; Rusch, Valerie W; Salgia, Ravi; Sepesi, Boris; Simone, Charles B; Sridhara, Rajeshwari; Szlosarek, Peter; Taioli, Emanuela; Tsao, Ming-Sound; Yang, Haining; Zauderer, Marjorie G; Malik, Shakun M.
Afiliação
  • Tsao AS; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
  • Lindwasser OW; Coordinating Center for Clinical Trials, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Adjei AA; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
  • Adusumilli PS; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Beyers ML; Emmes Corporation, Rockville, Maryland.
  • Blumenthal GM; U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Bueno R; Thoracic Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
  • Burt BM; Department of Surgery, Division of Thoracic Surgery, Baylor College of Medicine, Houston, Texas.
  • Carbone M; University of Hawaii Cancer Center, Honolulu, Hawaii.
  • Dahlberg SE; Department of Biostatistics, Dana Farber Cancer Institute, Boston, Massachusetts.
  • de Perrot M; Division of Thoracic Surgery, Toronto General Hospital, Toronto, Ontario, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Fennell DA; Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom; University Hospitals of Leicester, Leicester, United Kingdom.
  • Friedberg J; Department of Thoracic Surgery, University of Maryland Cancer Center, Baltimore, Maryland.
  • Gill RR; Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Gomez DR; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
  • Harpole DH; Division of Cardiothoracic Surgery, Department of Surgery, Duke University, Durham, North Carolina.
  • Hassan R; Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Hesdorffer M; Mesothelioma Applied Research Foundation, Alexandria, Virginia.
  • Hirsch FR; University of Colorado Cancer Center, IASLC, Denver, Colorado.
  • Hmeljak J; The Company of Biologists, Cambridge, United Kingdom.
  • Kindler HL; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.
  • Korn EL; Biometric Research Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Liu G; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Mansfield AS; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
  • Nowak AK; Medical School, University of Western Australia, Perth, Western Australia, Australia; National Center for Asbestos Related Diseases, University of Western Australia, Perth, Western Australia, Australia.
  • Pass HI; Department of Cardiothoracic Surgery, New York University, Langone Medical Center, New York, New York.
  • Peikert T; Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota.
  • Rimner A; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Robinson BWS; National Centre for Asbestos Related Disease, University of Western Australia, Nedlands, Western Australia, Australia; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
  • Rosenzweig KE; Department of Radiation Oncology, Mount Sinai Medical Center, New York, New York.
  • Rusch VW; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Salgia R; Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California.
  • Sepesi B; Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
  • Simone CB; Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, Maryland.
  • Sridhara R; Emmes Corporation, Rockville, Maryland.
  • Szlosarek P; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Taioli E; Epidemiology, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Tsao MS; Department of Pathology, University of Toronto, Toronto, Ontario, Canada; Department of Pathology, Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Yang H; Department of Surgery, Division of Thoracic Surgery, Baylor College of Medicine, Houston, Texas.
  • Zauderer MG; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Malik SM; Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: shakun.malik@nih.gov.
J Thorac Oncol ; 13(11): 1655-1667, 2018 11.
Article em En | MEDLINE | ID: mdl-30266660
On March 28- 29, 2017, the National Cancer Institute (NCI) Thoracic Malignacy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation convened the NCI-International Association for the Study of Lung Cancer- Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting in Bethesda, Maryland. The goal of the meeting was to bring together lead academicians, clinicians, scientists, and the U.S. Food and Drug Administration to focus on the development of clinical trials for patients in whom malignant pleural mesothelioma has been diagnosed. In light of the discovery of new cancer targets affecting the clinical development of novel agents and immunotherapies in malignant mesothelioma, the objective of this meeting was to assemble a consensus on at least two or three practice-changing multimodality clinical trials to be conducted through NCI's National Clinical Trials Network.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pulmonares / Mesotelioma Tipo de estudo: Guideline / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: J Thorac Oncol Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pulmonares / Mesotelioma Tipo de estudo: Guideline / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: J Thorac Oncol Ano de publicação: 2018 Tipo de documento: Article